DelveInsight's Airway Clearance Devices for Cystic Fibrosis Market Insights report provides the current and forecast market analysis, indiv ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
The US Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for brensocatib for patients with ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...
BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...
Cystic fibrosis is a genetic disorder that changes a vital protein in the body, causing a buildup of thick and sticky mucus, ...
The Bridgewater, N.J., biopharmaceutical company said brensocatib has the potential to become the first and only approved treatment for non-cystic fibrosis bronchiectasis, which causes the lungs' ...
Insmed (INSM) announced that the U.S. FDA has accepted the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback